目的 检测Claudin-1蛋白在非小细胞肺癌（NSCLC）原发癌组织及其淋巴结转移癌组织中的表达，并探讨其与NSCLC各临床病理特征和预后的关系。 方法 利用组织芯片技术，采用免疫组织化学染色方法检测Claudin-1在1998年1月－2003年12月收集的279例NSCLC原发癌组织及其55例淋巴结转移癌组织、54例癌旁正常肺组织中的表达。运用SPSS 13.00统计软件对相关数据进行统计分析。 结果 Claudin-1在279例NSCLC原发癌组织和55例淋巴结转移癌组织中的阳性表达率分别为69.9%和50.9%，在鳞癌和腺癌中的阳性表达率分别为83.7%和55.7%，在高、中分化癌组和低分化癌组中的阳性表达率分别为78.6%和62.7%。Claudin-1在原发癌组织中的阳性表达率高于其淋巴结转移癌组织（P＜0.05）；在鳞癌中的阳性表达率高于腺癌（P＜0.05），且在高、中分化癌组中的阳性表达率高于低分化癌（P＜0.05）。Claudin-1阳性表达之NSCLC患者的生存率高于阴性表达者（P＜0.05）。 结论 Claudin-1在NSCLC中的表达与患者的组织学类型及病理分级有关，且Claudin-1是NSCLC侵袭、转移的抑制因子，并且可能是一个有用的预后因子。
Objective To investigate the expression of claudin-1 in breast tumor tissues and the relationship of development and progress of breast neoplasm．Methods The expressions of claudin-1 in 89 cases of breast cancer and 37 benign breast diseases were tested by tissue chip technology and immunohistochemistry．The relationships of claudin-1 expression to the lymph node metastasis，TNM staging，maximum diameter of the tumor，and histology grade were statistically analyzed．Results The expression of claudin-1 in the breast cancer was significantly lower than that in the benign breast disease（χ2=19.20，P=0.000 2）．The claudin-1 expression in the patients with lymph node metastasis was significantly lower than that without lymph node metastasis （χ2=3.85，P=0.049 7）．The claudin-1 expression in the stageⅢ of TNM staging was weaker than that in the stage Ⅰ（χ2=5.29，P=0.021 4） and stage Ⅱ （χ2=7.46，P=0.006 3），respectively. There was no significant difference of the claudin-1 expression in the different maximum diameters of tumor （χ2=1.58，P=0.453 8） or histology grades （χ2=1.02，P=0.600 5），respectively．Conclusions The expression of claudin-1 might be correlated with the occurrence，development，and metastasis in breast tumor．It may be one of the potential indicator for lymph node metastasis and prognosis assessment in breast cancer．